Might 3, 2024 – Little has modified within the therapy of atrial fibrillation (AF) over the previous 15 years – up to now. AF is an irregular, usually very quick heartbeat. Typical remedy makes use of a catheter to ship excessive warmth or cryothermy to create lesions within the coronary heart to cease AF. Though considerably uncommon, this vitality can injury surrounding constructions, together with the esophagus, resulting in problems and even loss of life.
As of late 2023, each Medtronic (PulseSelect™ is a brand new process referred to as renal denervation) and Boston Scientific (FARAPULSE™) have obtained FDA approval for his or her proposed therapy of AF. Johnson and Johnson and Abbott may comply with the market with their very own answer1.
In Europe, early adopters are reportedly paying about double the price of their present ablation catheters. These new therapies have vital security and affected person care advantages, and vital progress on this class is predicted over the following decade.2.